Opinion: Novartis' generics move shows U.S. policy discourages innovation

03/16/2005 | Forbes

The move by European drugmaker Novartis to buy two generic drug companies is a result of U.S. government policies that "place short-term savings ahead of long-term research and development," writes Dr. Scott Gottlieb, editor of Forbes/Gottlieb Medical Technology Investor. If Novartis had entered the generics market 10 years earlier, leukemia patients would be without its breakthrough Gleevec drug today, he says.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC